drugset / Trial / NCT02622334
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
Timeline
- Start
- 2015-12-29
- Primary completion
- 2016-07-28
- Completion
- 2016-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latanoprost | Small molecule | 0.005 % | Topical |
| Subject | RO5093151 | Unknown | 0.1 % | Topical |
| Subject | RO5093151 | Unknown | 0.5 % | Topical |
| Subject | RO5093151 | Unknown | 1 % | Topical |